Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2007

PolyMedix Lands SBIR Grant for Anticoagulant Antagonists

  • PolyMedix received a phase 1 SBIR grant from the National Heart, Lung, and Blood Institute. The six-month, $100,000 backing will support the development of biomimetic compounds as anticoagulant antagonists.

    PolyMedix says that it the funding will go toward the company’s continued efforts to develop new compounds as antagonists to heparin and low molecular weight heparin. It calls these compounds heptagonists.

    PolyMedix hopes to file an IND application during the first quarter of 2008. Upon successful completion of the phase 1 portion of the work, PolyMedix plans to submit a request for additional funding.

    This award reportedly is the fifth SBIR grant awarded to the company. Previous grants totaled $3.5 million and were given in support of antibiotic development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »